3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Early Intervention, Educational
6
Oxaliplatin
5
Methods
4
Cisplatin
4
pembrolizumab
3
Trastuzumab
3
Surveys and Questionnaires
3
Specimen Handling
3
Leucovorin
3
Fluorouracil
3
Carboplatin
3
X-Rays
2
Radiotherapy
2
Observation
2
Magnetic Resonance Spectroscopy
2
Magnetic Resonance Imaging
2
Irinotecan
2
Interleukin-12 Subunit p35
2
Gemcitabine
2
Cyclophosphamide
2
Counseling
2
Cetuximab
2
Capecitabine
2
Biopsy
2
veliparib
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
sodium thiosulfate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
Technetium-99
×
Gynecologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled